Iron Studies Made Simple: Pattern Recognition for the Busy NP

 

Iron Studies Made Simple: Pattern Recognition for the Busy NP

Four numbers, four patterns—and the one pitfall that makes ferritin lie to you every time.

Iron studies are ordered constantly in primary care, yet they're consistently misinterpreted. The most common mistake? Checking a ferritin alone and calling it a day. In your autoimmune, inflammatory, and chronically ill patients, a single ferritin can be profoundly misleading. Let's learn the patterns.

The Four Tests (and What Each Measures)

• Serum Ferritin — Reflects iron stores. The most sensitive early marker of iron deficiency when inflammation is absent. But it's an acute-phase reactant—levels rise with inflammation, infection, liver disease, obesity, and malignancy, masking true iron deficiency.
• Serum Iron — The amount of iron circulating in the blood, mostly bound to transferrin. Highly variable (diurnal fluctuation, affected by recent meals). Low in both iron deficiency AND anemia of chronic disease. Not useful in isolation.
• TIBC (Total Iron-Binding Capacity) — Reflects available transferrin binding sites. Essentially a proxy for transferrin levels. High in iron deficiency (body makes more transferrin to scavenge iron), low in inflammation/chronic disease (transferrin production suppressed by cytokines).
• Transferrin Saturation (TSAT) — Serum iron ÷ TIBC × 100. Tells you what percentage of transferrin's seats are occupied. Low (<20%) in iron deficiency. High (>45%) raises concern for iron overload.

The Key Principle

No single iron test is diagnostic on its own. Interpretation requires pattern recognition across all four tests, correlated with the clinical context (especially inflammation status). Always order the complete panel, not just ferritin.

The Patterns: Your Diagnostic Cheat Sheet

Condition	Ferritin	Serum Iron	TIBC	TSAT
Iron Deficiency Anemia	↓ Low (<30)	↓ Low	↑ High	↓ Low (<20%)
Anemia of Chronic Disease	↑ Normal/High	↓ Low	↓ Low/Normal	↓ Low/Normal
Mixed (IDA + ACD)	Normal (misleading!)	↓ Low	Variable	↓ Low
Iron Overload (Hemochromatosis)	↑↑ Very High	↑ High	↓ Low/Normal	↑ High (>45%)
Chronic Liver Disease	↑ High	↑ High	Variable	↑ High
Pregnancy (late)	↓ Low	↓ Low	↑ High	↓ Low

The Pitfalls

1. Ferritin Is a Liar (in Inflammatory States)

This is the single most important pitfall in iron studies. Ferritin is an acute-phase reactant. In your patients with RA, SLE, IBD, chronic infections, malignancy, obesity, or any active inflammatory state, ferritin can be normal or elevated despite true iron deficiency. A "normal" ferritin of 80 in an SLE patient with a CRP of 45 may be masking severe iron deficiency.

The Rule

In patients with active inflammation, use a ferritin cutoff of <100 µg/L (not <15 or <30) to detect iron deficiency, combined with a TSAT <20%. The WHO's traditional cutoff of 15 misses the majority of iron-deficient patients who have concurrent inflammation. Always check CRP alongside iron studies to know if inflammation is confounding the ferritin.

2. Serum Iron Fluctuates Wildly

Serum iron has up to 30% daily variation due to diurnal rhythm and dietary intake. It's highest in the morning and drops in the afternoon. A single random serum iron is nearly useless for diagnosis. Always draw iron studies fasting, in the morning, and rely on the full pattern rather than serum iron alone.

3. Anemia of Chronic Disease Looks Like Iron Deficiency (But Isn't)

Both conditions have low serum iron and low TSAT. The distinguishing feature: in ACD, ferritin is normal or high and TIBC is low or normal. In true iron deficiency, ferritin is low and TIBC is high. The body's iron isn't deficient in ACD—it's sequestered in macrophages by hepcidin, making it unavailable for erythropoiesis despite adequate stores.

4. Mixed Iron Deficiency + Chronic Disease: The Hardest Pattern

This is where it gets tricky. A patient with RA who also has iron deficiency from NSAID-related GI bleeding will have a ferritin that's been artificially inflated by inflammation, masking the deficiency. TSAT <20% with elevated CRP is your best clue. Soluble transferrin receptor (sTfR), when available, can help—it rises in true iron deficiency but is unaffected by inflammation.

5. Don't Treat Iron Overload Without Confirming

A high ferritin doesn't always mean iron overload. Exclude inflammation, liver disease, alcohol use, obesity, metabolic syndrome, and malignancy first. If TSAT is >45% AND ferritin is persistently elevated after excluding these causes, then pursue hereditary hemochromatosis workup (HFE gene testing).

6. Iron Deficiency Without Anemia Is Real

Fatigue, brain fog, restless legs, hair loss, and exercise intolerance can all occur with iron deficiency before the hemoglobin drops. A ferritin <30 with symptoms warrants treatment even if the CBC is normal. Don't wait for anemia to treat iron deficiency.

7. Always Ask "Why?"

Iron deficiency in a postmenopausal woman or any man requires GI evaluation until proven otherwise. Don't just hand them iron pills—look for the source of blood loss. Colon cancer, celiac disease, and H. pylori gastritis are all on the differential.

The Autoimmune Connection

For your autoimmune patients, iron studies are complicated by chronic inflammation at every turn:

• SLE, RA, IBD: Ferritin elevated by inflammation; use TSAT and higher ferritin cutoffs
• Celiac disease: Iron deficiency is often the presenting feature (malabsorption)
• Autoimmune gastritis: Pernicious anemia AND iron deficiency can coexist
• Chronic kidney disease: Functional iron deficiency (adequate stores but impaired utilization); guidelines use TSAT <20% and ferritin <100 as treatment thresholds
• Heart failure: Iron deficiency (TSAT <20% or ferritin <100) independently worsens outcomes; IV iron improves symptoms regardless of anemia status

Quick-Reference: When to Order and How to Interpret

Clinical Scenario	Order	Key Interpretation
Microcytic anemia	Full iron panel + CRP + CBC	Classic IDA: low ferritin, low iron, high TIBC, low TSAT
Anemia + active inflammation	Full iron panel + CRP	Ferritin may be falsely normal; rely on TSAT <20% and consider sTfR if available
Fatigue without anemia	Ferritin + TSAT	Ferritin <30 with symptoms = treat. Don't wait for anemia.
Elevated ferritin, unclear cause	Full iron panel + CRP + LFTs + HbA1c	Rule out inflammation, liver disease, metabolic syndrome before assuming overload
Suspected hemochromatosis	Fasting TSAT + ferritin	TSAT >45% + high ferritin after excluding secondary causes → HFE gene testing
Postmenopausal woman or any man with IDA	Full iron panel + GI referral	Investigate for source of blood loss. Colon cancer until proven otherwise.

Bottom Line

Iron studies are pattern recognition, not single-number diagnosis. Ferritin alone is not enough—especially in your inflammatory and autoimmune patients, where it lies to you constantly. Always order the full panel with CRP. Learn the four patterns (IDA, ACD, mixed, overload) and you'll interpret iron studies correctly in any clinical context.

Stay sharp out there.

Syphilis Screening: Traditional vs. Reverse Algorithms, False Positives, and the SLE Connection

 

Syphilis Screening: Traditional vs. Reverse Algorithms, False Positives, and the SLE Connection

Two tests, two algorithms, one disease that's surging back—and the autoimmune pitfall that keeps tripping everyone up.

Syphilis is back. Rates in the US have been climbing steadily, congenital syphilis cases have skyrocketed, and the CDC has made this a public health priority. For NPs in primary care, prenatal care, and urgent care, understanding the screening algorithms isn't optional anymore—it's essential. And the fact that your lab may be using a different algorithm than the one you learned in school makes it even more critical to know what you're looking at.

The Two Categories of Tests

Before we get to algorithms, you need to understand the two fundamentally different types of syphilis tests:

Nontreponemal Tests (RPR, VDRL)

• Detect antibodies to cardiolipin-cholesterol-lecithin antigens released from damaged host cells and from T. pallidum itself
• NOT specific to syphilis—they detect tissue damage, not the organism
• Reported as a quantitative titer (1:2, 1:4, 1:8, etc.)
• Titers correlate with disease activity and are used to monitor treatment response
• A fourfold change in titer (two dilutions, e.g., 1:16 to 1:4) = clinically significant change
• Become negative after successful treatment in most patients (though some remain "serofast" at a low titer indefinitely)
• Can be falsely positive in many conditions (see pitfalls below)

Treponemal Tests (FTA-ABS, TP-PA, EIA/CIA)

• Detect antibodies specific to Treponema pallidum
• Confirm that a nontreponemal positive is real syphilis (traditional algorithm)
• OR serve as the initial screen (reverse algorithm)
• Remain positive for life in 75–85% of patients after treatment—they are NOT useful for monitoring treatment response
• Cannot distinguish active from past/treated infection on their own
• False positives can occur with Lyme disease and other non-syphilis treponemal infections

The Two Algorithms

Traditional Algorithm

Screen with a nontreponemal test, confirm with a treponemal test.

1. RPR or VDRL (screening)
2. ↓ If reactive:
3. Treponemal test (FTA-ABS or TP-PA) to confirm
4. ↓ Both reactive = syphilis (stage based on clinical findings and titer)

Pros: Familiar, cost-effective, fewer false-positive workups in low-prevalence settings. RPR titer immediately available for staging and monitoring.
Cons: Can miss early primary syphilis and late latent syphilis (RPR may be nonreactive). Higher false-positive rate for the screening step.

Reverse Algorithm

Screen with a treponemal test, then get a nontreponemal titer.

1. Treponemal immunoassay (EIA or CIA—automated) as the screen
2. ↓ If reactive:
3. RPR (quantitative titer) to assess disease activity
4. ↓ If RPR is also reactive = syphilis (stage and treat)
5. ↓ If RPR is nonreactive (discordant):
6. Second, different treponemal test (TP-PA) as tiebreaker

Pros: Automated, high-throughput, catches latent syphilis and previously treated cases that RPR would miss. More sensitive overall.
Cons: Generates more discordant results requiring tiebreaker testing. Can identify past treated syphilis (treponemal tests stay positive for life), leading to unnecessary workups and overtreatment if not interpreted carefully.

Know Your Lab

Find out which algorithm your lab uses. Many high-volume commercial labs have switched to the reverse algorithm because of automation. If you're interpreting results without knowing which algorithm generated them, you can easily misread what a "positive syphilis screen" means. Ask your lab.

Interpreting the Results: The Cheat Sheet

Nontreponemal (RPR/VDRL)	Treponemal (FTA-ABS/TP-PA/EIA)	Interpretation
Nonreactive	Not done or nonreactive	No syphilis detected. (But can miss very early primary syphilis—both tests may be negative in the first 1–2 weeks of chancre.)
Reactive	Reactive	Syphilis confirmed. Stage and treat based on clinical findings and RPR titer. Could be active or past inadequately treated infection.
Reactive	Nonreactive	Biologic false positive RPR. The patient does NOT have syphilis. Investigate causes (see pitfalls).
Nonreactive	Reactive	Discordant (reverse algorithm scenario). Could be: (1) past treated syphilis (most common), (2) late latent syphilis with waning RPR, (3) very early primary syphilis, or (4) false-positive treponemal screen. Resolve with a second, different treponemal test (TP-PA).
Low-titer reactive (1:1–1:2)	Reactive	Could be serofast state (patient previously treated, RPR won't fully decline) or early/late infection. Correlate with treatment history and clinical exam.

The Pitfalls: Where NPs Get Tripped Up

1. The Biologic False-Positive RPR—and the SLE Connection

This is the pitfall that ties directly into the autoimmune series. The RPR and VDRL use cardiolipin as their antigen. Patients with antiphospholipid antibodies—including anticardiolipin antibodies—will have a false-positive RPR/VDRL because the test is detecting their autoantibodies, not a syphilis infection.

Conditions that cause biologic false-positive RPR/VDRL:

• SLE — the classic autoimmune culprit; up to 10–20% of SLE patients may have a false-positive RPR
• Antiphospholipid syndrome — by definition, these patients have anticardiolipin antibodies
• Pregnancy
• HIV infection
• IV drug use
• Other infections: hepatitis, EBV, malaria, tuberculosis, endocarditis
• Chronic liver disease
• Advanced age
• Recent vaccination

The Autoimmune Pearl

A positive RPR with a negative treponemal test in a young woman should make you think about SLE and antiphospholipid syndrome, not just dismiss it as a lab error. In fact, a biologic false-positive syphilis test was historically one of the earliest recognized clues to antiphospholipid antibody positivity. If you see this pattern, check an antiphospholipid panel (lupus anticoagulant, anticardiolipin, anti-β2GPI) and consider ANA testing.

2. The "Discordant Reverse Algorithm" Trap

With the reverse algorithm, you'll frequently encounter the scenario: treponemal screen reactive, RPR nonreactive. This generates a lot of confusion and unnecessary treatment. In most cases, this represents a patient with past, adequately treated syphilis whose treponemal antibodies persist for life. The key is the tiebreaker TP-PA:

• TP-PA reactive: The patient had real syphilis at some point. If no history of treatment, treat for late latent syphilis. If previously treated, no action needed (unless reexposure is suspected).
• TP-PA nonreactive: The original treponemal screen was a false positive. No syphilis. No treatment.

3. RPR Titers Are Not Interchangeable with VDRL

RPR and VDRL are both nontreponemal tests, but their titers are not directly comparable. An RPR of 1:8 and a VDRL of 1:8 may not represent the same antibody level. Always use the same test (and ideally the same lab) for serial monitoring. A fourfold change (two dilutions) is required to call a result clinically significant.

4. The Prozone Phenomenon

In secondary syphilis, antibody levels can be so high that they overwhelm the nontreponemal assay, causing a false-negative RPR (or a paradoxically low titer). This is called the prozone effect. If you have a patient with classic secondary syphilis symptoms (diffuse rash including palms/soles, mucous patches, condylomata lata) and a nonreactive or weakly reactive RPR, request that the lab perform serial dilutions to unmask a high-titer positive.

Clinical Pearl

If it looks like secondary syphilis clinically but the RPR is negative or suspiciously low, call your lab and ask for dilution testing. The prozone phenomenon is rare but real, and missing secondary syphilis has serious consequences.

5. Treponemal Tests Stay Positive for Life

Once treated, treponemal tests (FTA-ABS, TP-PA, EIA) remain reactive in 75–85% of patients forever. This does NOT indicate reinfection or treatment failure. Only 15–25% of patients treated during primary syphilis will eventually revert to seronegative. Do not use treponemal tests to monitor treatment response. Use the RPR titer.

6. Very Early Primary Syphilis Can Be Seronegative

In the first 1–2 weeks after a chancre appears, both nontreponemal and treponemal tests may still be negative. If you see a painless genital ulcer consistent with a chancre, treat empirically and retest in 2–4 weeks. Don't let a negative serology stop you from treating a clinical primary syphilis.

7. The Serofast State

Some patients, even after adequate treatment, will maintain a persistently low-titer RPR (typically 1:1 to 1:4) indefinitely. This is called the serofast state and does NOT indicate treatment failure or reinfection. It's more common in patients treated for late-stage syphilis. A serofast patient should be monitored but does not need retreatment unless there's clinical evidence of active disease or a fourfold rise in titer.

8. Pregnancy: Test Three Times

Given the surge in congenital syphilis, current guidelines (CDC, ACOG) now recommend screening pregnant patients three times: at the first prenatal visit, early in the third trimester (~28 weeks), and at delivery. This is non-negotiable. Congenital syphilis is devastating and entirely preventable with timely treatment.

When Should NPs Order Syphilis Testing?

Test When You See

• Any painless genital, anal, or oral ulcer (suspect primary syphilis)
• Diffuse rash involving palms and soles (suspect secondary syphilis)
• Mucous patches, condylomata lata, patchy alopecia
• All pregnant patients (three times during pregnancy)
• All patients diagnosed with another STI (HIV, gonorrhea, chlamydia)
• MSM (men who have sex with men)—per CDC, screen at least annually
• HIV-positive patients—screen at baseline and annually
• New sexual partner evaluation or sexual assault follow-up
• Unexplained neurologic symptoms in a patient with history of syphilis or risk factors
• Biologic false-positive RPR as part of a broader autoimmune workup (check aPL panel)

The SLE/APS Connection: A Summary for Your Autoimmune Patients

Tying It Together

In a patient with SLE or suspected antiphospholipid syndrome:

• A positive RPR/VDRL + negative treponemal test = biologic false positive, NOT syphilis. This is a clue to check antiphospholipid antibodies.
• Conversely, a positive treponemal test in an SLE patient should be taken seriously—the treponemal test is specific for syphilis and is NOT affected by antiphospholipid antibodies.
• The biologic false-positive syphilis test was historically one of the earliest recognized markers of antiphospholipid antibodies—before aPL assays existed, this was how clinicians first identified the autoantibodies that would later define antiphospholipid syndrome.
• Always confirm a reactive RPR with a treponemal test before diagnosing syphilis in an autoimmune patient. And always investigate a false-positive RPR for underlying autoimmune disease in a young patient.

Quick-Reference: The Decision Matrix

Scenario	What to Do
RPR reactive, treponemal reactive	Syphilis confirmed. Stage and treat. Monitor RPR titers.
RPR reactive, treponemal nonreactive	Biologic false positive. No syphilis. Investigate: SLE? APS? Pregnancy? Infection?
Treponemal screen reactive, RPR nonreactive (reverse algorithm)	Order TP-PA tiebreaker. If TP-PA reactive + no treatment history → treat for late latent. If TP-PA nonreactive → false-positive screen.
Previously treated, low-titer serofast RPR (1:1–1:4)	Monitor. No retreatment unless fourfold rise or clinical symptoms.
Clinical chancre, serology negative	Treat empirically. Retest in 2–4 weeks. Very early primary can be seronegative.
Pregnant patient	Screen at first visit, ~28 weeks, and delivery. Treat immediately if positive. Don't wait for confirmatory testing to treat in pregnancy.

Bottom Line

Syphilis testing is not complicated once you understand the two test types and the two algorithms. The critical points: know which algorithm your lab uses, never diagnose syphilis on a nontreponemal test alone, never use a treponemal test to monitor treatment, and always investigate a biologic false-positive RPR for underlying autoimmune disease. For your autoimmune patients, the RPR is a test that speaks two languages—infection and autoimmunity—and knowing which one it's speaking requires the treponemal test as the translator.

And with congenital syphilis surging, screen every pregnant patient three times. No exceptions.

Stay sharp out there.

Thyroid Antibodies Decoded: Which to Order, When They Matter, and When They Don't

 

Thyroid Antibodies Decoded: Which to Order, When They Matter, and When They Don't

Three antibodies, three different clinical stories—and the autoimmune crossover that ties them to everything else you're managing.

Thyroid antibody testing is one of the most commonly ordered—and most commonly misinterpreted—panels in primary care. Every week I see providers ordering the full antibody panel on every patient with an abnormal TSH, or panicking about a positive anti-TPO in someone with a perfectly normal thyroid. Let's sort out what each antibody actually tells you and when it changes your management.

The Three Thyroid Antibodies

Anti-TPO (Thyroid Peroxidase Antibody)

Target: Thyroid Peroxidase Enzyme

The workhorse antibody for Hashimoto's thyroiditis. TPO is the enzyme that catalyzes thyroid hormone synthesis. Anti-TPO antibodies activate complement and are directly involved in thyroid tissue destruction. Present in ~95% of Hashimoto's patients and ~70% of Graves' patients. This is the most sensitive thyroid antibody for detecting autoimmune thyroid disease (AITD).

The catch: anti-TPO is also positive in about 10% of the general population who have no thyroid disease—and this prevalence rises with age and female sex. A positive anti-TPO alone, without thyroid dysfunction, doesn't require treatment.

Anti-Tg (Thyroglobulin Antibody)

Target: Thyroglobulin Protein

Present in 30–50% of Hashimoto's patients and at about half that rate in Graves' disease. Less sensitive than anti-TPO for diagnosing AITD. Per Mayo Clinic Laboratories guidance, anti-Tg should only be ordered if anti-TPO is negative but clinical suspicion for AITD remains high.

Critical second role: Anti-Tg is essential in the monitoring of differentiated thyroid cancer after treatment. Thyroglobulin (Tg) is used as a tumor marker post-thyroidectomy, but anti-Tg antibodies interfere with the Tg assay—causing falsely low results on immunometric assays. If anti-Tg is present, the Tg tumor marker is unreliable, and rising anti-Tg titers themselves may indicate recurrence.

TRAb / TSI (TSH Receptor Antibodies / Thyroid-Stimulating Immunoglobulin)

Target: TSH Receptor

The Graves' disease antibody. TSI binds to the TSH receptor and mimics TSH, causing unregulated thyroid hormone production. TSI is ~96% sensitive and ~99% specific for Graves' disease. There are actually three types of TSH receptor antibodies—stimulating (TSI), blocking, and neutral—but TSI is the clinically actionable one.

Nomenclature warning: TRAb, TBII, TSI, and LATS all refer to related but distinct assays. TRAb/TBII measures all receptor antibodies (stimulating + blocking + neutral). TSI measures only the stimulating type. In most clinical contexts, TSI is what you want when confirming Graves' disease.

The Master Decision Table: Which Antibody, When

Clinical Scenario	What to Order	Why
Elevated TSH, suspect Hashimoto's	Anti-TPO	Most sensitive marker; confirms autoimmune etiology. Anti-Tg adds little if TPO is positive.
Elevated TSH, anti-TPO negative, still suspect AITD	Anti-Tg	~5% of Hashimoto's patients are TPO-negative but Tg-positive
Subclinical hypothyroidism (mildly elevated TSH, normal T4)	Anti-TPO	Positive anti-TPO predicts progression to overt hypothyroidism; may influence treatment decision
Suppressed TSH, suspect Graves' disease	TSI (or TRAb)	Confirms Graves' vs. other causes of hyperthyroidism (toxic nodule, thyroiditis, exogenous T4)
Hyperthyroidism when radioactive iodine uptake is contraindicated or unavailable	TSI	Can confirm Graves' without imaging
Pregnant with Graves' disease (or history of Graves')	TRAb/TSI	Maternal TRAb crosses the placenta; high titers predict neonatal thyrotoxicosis risk
Post-thyroidectomy thyroid cancer monitoring	Anti-Tg (with every thyroglobulin measurement)	Anti-Tg interferes with Tg tumor marker assays; rising anti-Tg may signal recurrence
Positive ANA workup, looking for cause	Anti-TPO + Anti-Tg	Thyroid antibodies may be the sole explanation for ANA positivity (speckled or homogeneous pattern)
Euthyroid patient, no symptoms	Nothing	Don't screen asymptomatic patients for thyroid antibodies

The Pitfalls: What Trips Up Clinicians

1. Positive Anti-TPO in a Euthyroid Patient ≠ Disease

About 10% of the general population—and up to 25% of women over 60—will have positive anti-TPO with completely normal thyroid function. This does not require treatment. It does mean the patient has a higher risk of developing overt hypothyroidism over time (about 2–4% per year if TSH is already in the high-normal range). The appropriate response is periodic TSH monitoring, not levothyroxine.

Clinical Pearl

The combination of positive anti-TPO + mildly elevated TSH is where the treatment decision gets nuanced. Many endocrinologists will recommend starting levothyroxine in this scenario, especially if the patient is symptomatic, has a goiter, is trying to conceive, or has TSH >10. Antibody-negative subclinical hypothyroidism is less likely to progress and may be observed.

2. Don't Routinely Order Anti-Tg for Hashimoto's Diagnosis

Anti-TPO is more sensitive and has equal specificity. Ordering both together for initial diagnosis adds cost without meaningful diagnostic yield. Save anti-Tg for when TPO is negative but suspicion is high, or for thyroid cancer monitoring.

3. Thyroid Antibodies Can Explain a Positive ANA

This was highlighted in the Bellocchi autoimmune serologic testing review that started this whole blog series. Anti-TPO and anti-Tg antibodies can cause ANA positivity, typically with a speckled or homogeneous pattern. In a patient with positive ANA but no clinical features of CTD, always check thyroid antibodies. Hashimoto's may be the sole explanation—and it's far more common than lupus.

Connecting the Dots

If you're working up a positive ANA and the patient has no joint pain, no rash, no Raynaud's, and no oral ulcers—but they do have fatigue and a TSH of 6.2—check anti-TPO before chasing an ENA panel. You may save the patient a rheumatology referral.

4. TSI vs. TRAb: Know What You're Ordering

The nomenclature is genuinely confusing. TRAb (or TBII) assays measure all TSH receptor antibodies—stimulating, blocking, and neutral. TSI assays specifically measure only stimulating antibodies. For confirming Graves' disease, TSI is more specific. Some labs report "TRAb" when they mean TBII; others use TRAb to mean TSI. Know what your lab is actually running, and when in doubt, specifically order TSI.

5. Graves' Disease Patients Can Be TRAb/TSI-Negative (Rarely)

About 5% of Graves' patients are seronegative for TSI. If the clinical picture is classic (suppressed TSH, elevated free T4, diffuse goiter, ophthalmopathy) but TSI is negative, a radioactive iodine uptake scan will confirm the diagnosis. Don't exclude Graves' based solely on a negative antibody.

6. Biotin Interference

This is a practical pitfall that catches people. Biotin (vitamin B7)—found in many hair, skin, and nail supplements—can interfere with immunoassays used for thyroid testing, including antibody tests. It can cause falsely low TSH and falsely high free T4 (mimicking hyperthyroidism), and can interfere with antibody measurements. Patients should stop biotin supplements for at least 12 hours (some labs recommend 48–72 hours) before thyroid testing.

7. Pregnancy: When Antibodies Really Matter

Thyroid antibodies take on special significance in pregnancy:

• Positive anti-TPO in euthyroid pregnant women increases risk of miscarriage and preterm birth. Some guidelines recommend levothyroxine in this population, though this remains debated.
• TRAb/TSI in pregnant women with Graves' disease (active or history of Graves'): these antibodies cross the placenta and can cause neonatal thyrotoxicosis. Check TRAb/TSI in early pregnancy and again at 18–22 weeks; high titers warrant neonatal monitoring.
• Postpartum thyroiditis: anti-TPO positive women have a significantly higher risk of developing postpartum thyroiditis. Persistently elevated antibodies after postpartum thyroiditis predict permanent hypothyroidism.

8. Immune Checkpoint Inhibitor Thyroiditis

For NPs managing oncology patients: immune checkpoint inhibitors (pembrolizumab, nivolumab, ipilimumab) frequently cause thyroid adverse effects. Patients with pre-existing thyroid antibodies are at higher risk. Checking anti-TPO before starting immunotherapy can help predict who will develop thyroiditis, and thyroid function should be monitored throughout treatment.

The Autoimmune Cluster

Autoimmune thyroid disease rarely travels alone. If you diagnose Hashimoto's or Graves', keep these associated conditions on your radar:

• Type 1 diabetes — screen if symptomatic
• Celiac disease — consider if GI symptoms, anemia, or weight changes
• Pernicious anemia — check B12 and anti-intrinsic factor if macrocytic anemia
• Vitiligo, alopecia areata — skin manifestations of shared autoimmune susceptibility
• Addison's disease — rare but part of autoimmune polyglandular syndrome
• SLE, Sjögren's, RA — broader CTD spectrum
• Primary Raynaud's — may be associated with autoimmune thyroiditis

Quick-Reference: The Ordering Algorithm

TSH Result	Clinical Question	Order
Elevated (hypo)	Is this autoimmune?	Anti-TPO. If negative, consider anti-Tg.
Mildly elevated (subclinical)	Will this progress?	Anti-TPO (positive = higher risk of progression)
Suppressed (hyper)	Is this Graves'?	TSI (or TRAb). Do NOT use anti-TPO to diagnose Graves'.
Normal	ANA positive, no CTD features	Anti-TPO + anti-Tg (thyroid antibodies may explain ANA)
Normal	No symptoms, no clinical indication	Don't order thyroid antibodies
Any	Pregnant with Graves' (active or history)	TRAb/TSI (1st trimester and 18–22 weeks)
Any	Thyroid cancer monitoring post-treatment	Anti-Tg (with every thyroglobulin tumor marker)

Bottom Line

Thyroid antibody testing is powerful when used correctly. Anti-TPO is your go-to for Hashimoto's and subclinical hypothyroidism risk stratification. TSI is what confirms Graves'. Anti-Tg is a niche player—reserve it for TPO-negative suspected AITD and thyroid cancer monitoring. And remember: a positive antibody in a euthyroid patient is not a diagnosis. It's a risk factor that requires monitoring, not reflexive treatment.

Most importantly for this series: thyroid antibodies are the hidden explanation behind many "unexplained" positive ANAs. If you take nothing else from this post, remember to check anti-TPO and anti-Tg when you're chasing a positive ANA in a patient who just doesn't look like lupus.

Stay sharp out there.